CC
FATE icon

Claybrook Capital’s Fate Therapeutics FATE Stock Holding History

Claybrook Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-16,730
Closed -$1.45M – 164
2021
Q2 		$1.45M Buy
+16,730
New +$1.35M 0.47% 64

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Claybrook Capital's FATE Position: Q3 2021 in Review

Claybrook Capital sold out of Fate Therapeutics (FATE) in Q3 2021, closing a stake of 16,730 shares — an estimated $1.45M sold.

Claybrook Capital first reported a position in FATE in Q2 2021 and held it in 1 quarter. The position peaked at $1.45M in Q2 2021. 265 funds tracked by Wall St. Rank hold FATE as of Q3 2021.

  • Claybrook Capital reported no remaining Fate Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Claybrook Capital sold 16,730 Fate Therapeutics shares in Q3 2021, an estimated $1.45M.
  • Claybrook Capital first reported a position in Fate Therapeutics in Q2 2021 and held it in 1 quarter.
  • Claybrook Capital's Fate Therapeutics position peaked at $1.45M in Q2 2021.
  • 265 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2021.

Based on Claybrook Capital's 13F filing for Q3 2021, filed 15 Nov 2021.